Evidence map›Paper›PMID 37557073›Full record

ReviewStem cell reports2023

Cell transplantation-based regenerative medicine in liver diseases.

Vincenzo Cardinale, Nicolas Lanthier, Pedro M Baptista, Guido Carpino, Gianluca Carnevale, Giuseppe Orlando, Roberta Angelico, Tommaso Maria Manzia, Detlef Schuppan, Massimo Pinzani and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Scaffold implantationAnnals of surgical treatment and research · 2025
    Article
  13. Co-existing regeneration mechanisms in severe alcohol-related steatohepatitis.Translational gastroenterology and hepatology · 2025
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 6 countries.

Vincenzo CardinaleDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy. Electronic address: vincenzo.cardinale@uniroma1.it.
Nicolas LanthierService d'Hépato-gastroentérologie, Cliniques Universitaires Saint-Luc, Laboratory of Hepatogastroenterology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
Pedro M BaptistaInstituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas (CIBERehd), Madrid, Spain; Fundación ARAID, Zaragoza, Spain; Department of Biomedical and Aerospace Engineering, Universidad Carlos III de Madrid, Madrid, Spain.
Guido CarpinoDepartment of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University of Rome, Italy.
Gianluca CarnevaleDepartment of Surgery, Medicine, Dentistry, and Morphological Sciences with Interest in Transplant, Oncology, and Regenerative Medicine, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Giuseppe OrlandoSection of Transplantation, Department of Surgery, Wake Forest University School of Medicine, Winston Salem, NC, USA.
Roberta AngelicoHepatobiliary Surgery and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.
Tommaso Maria ManziaHepatobiliary Surgery and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.
Detlef SchuppanInstitute of Translational Immunology, Research Center for Immune Therapy, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Massimo PinzaniUCL Institute for Liver and Digestive Health, Division of Medicine, Royal Free Hospital, London, UK.
Domenico AlvaroDepartment of Translation and Precision Medicine, "Sapienza" University of Rome, Rome, Italy.
Rachele CiccocioppoGastroenterology Unit, Department of Medicine, A.O.U.I. Policlinico G.B. Rossi & University of Verona, Verona, Italy. Electronic address: rachele.ciccocioppo@univr.it.
Basak E UygunCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital, Harvard Medical School, Shriners Hospitals for Children, Boston, MA 02114, USA; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: buygun@mgh.harvard.edu.
Sapienza University of Rome · ITUniversity of Rome Tor Vergata · ITBeth Israel Deaconess Medical Center · USCliniques Universitaires Saint-Luc · BEInstituto de Investigación Sanitaria Aragón · ESShriners Hospitals for Children - Boston · USUniversity College London · GBUniversity of Modena and Reggio Emilia · ITUniversity of Verona · ITWake Forest University · US

Funding

Recellularization of Liver BioscaffoldsR01DK084053 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI UYGUN, BASAK ELIF, YARMUSH, MARTIN L · 2009 to 2020
$4.6M
NIDDK NIH HHS R01 DK084053
6 · The paper itself

Abstract

This review aims to evaluate the current preclinical state of liver bioengineering, the clinical context for liver cell therapies, the cell sources, the delivery routes, and the results of clinical trials for end-stage liver disease. Different clinical settings, such as inborn errors of metabolism, acute liver failure, chronic liver disease, liver cirrhosis, and acute-on-chronic liver failure, as well as multiple cellular sources were analyzed; namely, hepatocytes, hepatic progenitor cells, biliary tree stem/progenitor cells, mesenchymal stromal cells, and macrophages. The highly heterogeneous clinical scenario of liver disease and the availability of multiple cellular sources endowed with different biological properties make this a multidisciplinary translational research challenge. Data on each individual liver disease and more accurate endpoints are urgently needed, together with a characterization of the regenerative pathways leading to potential therapeutic benefit. Here, we critically review these topics and identify related research needs and perspectives in preclinical and clinical settings.

Indexed as

Liver DiseasesRegenerative MedicineHepatocytesHumansLiverStem Cell Transplantationacute liver failurecell therapycirrhosishepatocytesmacrophagesprogenitorsscaffoldsstem cells

Identifiers

PMID37557073
PMCPMC10444572
OpenAlexW4385666859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.